The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed

Bone Marrow Transplantation

Volumn 25, Issue 10, 2000, Pages 1053-1058

  Ringden O ^a,b   Labopin, M ^c   Gorin, N C ^c   Meloni, G ^d   Biaise, D ^e   Reiffers, J ^f   Carlson, K ^g   Fouillard, L ⁱ   Frassoni, F ^h  

^a Centre for Allogeneic Stem Cell Transplantation   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HÔPITAL SAINT ANTOINE   (France)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e INSTITUT PAOLI CALMETTES   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute leukaemia; Allogeneic bone marrow transplantation; Autologous stem cell transplantation; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; FEMALE; HLA MATCHING; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0034024209     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702409     Document Type: Article

References (25)

1. Burnett A, Eden O. The treatment of acute leukemia. Lancet 1997; 349: 270-275.
2. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998; 92: 1073-1090.
3. Rowe JM, Ciobanu N, Ascensao J et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Aim Intent Med 1994; 120: 143-158.
4. Schmilz N, Gratwohl A, Goldman JM, for Accreditation SubCommittee of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Bone Marrow Transplant 1996; 17: 471-477.
5. Burnett AK, Goldstone AH, Stevens RM et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
6. Hermans J, Suciu S, Stijnen T et al. Treatment of acute myelogenous leukaemia: an EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Oncol 1989; 25: 545-550.
7. Gorin NC, Labopin M, Fouillard L et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA-identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 18: 111-117.
8. Zittoun R, Mandelli F, Willemze R et al, for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne DeH'Adulto (GIMENA) Leukemia Cooperative Groups. Auto-
9. logous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukaemia. New Engl J Med 1995; 332: 217-223.
10. Reiffers J, Stoppa AM, Altai M et al, for the EBMT Group. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874-1882.
11. Ringdén O, Labopin M, Gluckman E et al, for the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) study. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Bone Marrow Transplant 1997; 19: 963-968.
12. Odom L, August CS, Githens JH et al. Remission of relapsed leukemia during a graft-versus-host reaction. A graft-versusleukemia reaction in man? Lancet 1978; 2: 537-540.
13. Weiden PL, Fluornoy N, Thomas ED et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. New Engl J Med 1979; 300: 1068-1073.
14. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-Ieukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
15. Ringdén O, Labopin M, Gluckman E et al, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921-929.
16. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Cox DR. Regression models and life-tables. JR Stat Soc (Series B) 1972; 34: 187-220.
19. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995; 13: 1023-1035.
20. Weite K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHugG-CSF): the first 10 years. Blood 1996; 88: 19071929.
21. Barrett AJ, Horowitz MM, Gale RP et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862-871.
22. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
23. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, -B, -DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
24. Ringdén O, Labopin M, Frassoni F et al, for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic bone marrow transplantation or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplant 1999; 24: 389-396.
25. Oakhill A, Pamphilon D, Potter M et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-578.